文献速递消化系统肿瘤

胃癌当前治疗与近期进展

Current treatment and recent progress in gastric cancer.
PubMed 文献 · CA Cancer J Clin · 2021-02-16

本文综述胃癌系统化疗、放疗、手术、免疫及靶向治疗证据,强调多学科治疗决策;可切除胃癌的三药化疗已被接受,可能代表局部病变细胞毒化疗平台期;基于MSI、PD-L1、HER2、TMB和EBV等生物标志物的分子分型正推动个体化系统治疗。

要点

  • 可切除胃癌已接受三药化疗,可能代表局部病变标准化疗平台期。
  • MSI、PD-L1、HER2、TMB和EBV等标志物正驱动系统治疗选择。
  • 胃癌东西方生物学差异增加基于国际试验确定标准治疗的复杂性。

核心结论

  • 胃癌多学科治疗对治疗选择至关重要,分子分型正推动个体化治疗。

研究设计与样本

  • 本文为综述,汇总胃癌系统化疗、放疗、手术、免疫治疗和靶向治疗的疗效证据。

主要发现

  • 系统化疗、放疗、手术、免疫治疗和靶向治疗在胃腺癌中均已被证明有效。
  • 可切除胃癌的三药化疗现已被接受,可能代表局部病变标准化疗的平台期。
  • 基于分子亚型的胃癌分类为个体化治疗提供了机会。

关键数值与推荐

  • MSI、PD-L1、HER2、TMB和EBV等生物标志物日益驱动系统治疗策略,并识别最可能从免疫和靶向治疗中获益的人群。

临床怎么用

  • 胃癌治疗选择应基于多学科团队决策。
  • 可切除胃癌可考虑三药化疗。
  • 系统治疗选择应结合MSI、PD-L1、HER2、TMB和EBV等生物标志物。

局限性

  • 东西方国家肿瘤生物学差异增加基于国际试验确定标准治疗的复杂性。
  • 分化较差的胃腺癌亚型及无免疫治疗活性标志物的人群仍存在显著研究机会。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gastric cancer is not a top-10 malignancy in the United States but represents one of the most common causes of cancer death worldwide. Biological differences between tumors from Eastern and Western countries add to the complexity of identifying standard-of-care therapy based on international trials. Systemic chemotherapy, radiotherapy, surgery, immunotherapy, and targeted therapy all have proven efficacy in gastric adenocarcinoma; therefore, multidisciplinary treatment is paramount to treatment selection. Triplet chemotherapy for resectable gastric cancer is now accepted and could represent a plateau of standard cytotoxic chemotherapy for localized disease. Classification of gastric cancer based on molecular subtypes is providing an opportunity for personalized therapy. Biomarkers, in particular microsatellite instability (MSI), programmed cell death ligand 1 (PD-L1), human epidermal growth factor receptor 2 (HER2), tumor mutation burden, and Epstein-Barr virus, are increasingly driving systemic therapy approaches and allowing for the identification of populations most likely to benefit from immunotherapy and targeted therapy. Significant research opportunities remain for the less differentiated histologic subtypes of gastric adenocarcinoma and those without markers of immunotherapy activity.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021. PMID: 33592120. doi:10.3322/caac.21657

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。